文献速递银屑病与炎症性皮肤病

银屑病患者生物制剂治疗的持续性:法国国家医疗保险数据库(SNIIRAM)16 545例生物制剂初治患者的真实世界分析

Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM).
PubMed 文献 · Br J Dermatol · 2018-09-23

基于法国国家医疗保险数据库2008至2016年数据,纳入16 545例生物制剂初治银屑病患者,评估生物制剂治疗持续性。Kaplan-Meier分析显示第1、3、5年持续性分别为61.9%、33.3%、22.6%,乌司奴单抗持续性高于其他生物制剂。作者认为真实世界非选择人群中生物制剂效果低于医生预期,长期疾病控制需多疗程不同生物制剂。

要点

  • 第1、3、5年生物制剂治疗持续性分别为61.9%、33.3%、22.6%。
  • 乌司奴单抗持续性高于其他生物制剂,但需谨慎解读因给药方式不同。
  • 约85%停用首个生物制剂的患者次年重新接受某种系统治疗,其中85%为生物制剂。

核心结论

  • 数据提示在真实世界非选择人群中,生物制剂效果低于医生此前所相信的水平。
  • 长期疾病控制需要多个疗程的不同生物制剂。

研究设计与样本

  • 全国性人群队列研究,数据来自法国国家医疗保险数据库(SNIIRAM)2008至2016年登记的所有成人银屑病患者。
  • 银屑病定义为2年内至少开具两次外用维生素D衍生物制剂处方。
  • 研究人群为生物制剂初治患者,即首次处方依那西普、英夫利西单抗、阿达木单抗或乌司奴单抗者。
  • 共16 545例生物制剂初治患者,平均年龄48.6岁,男性57.3%,平均随访3.6年。

主要发现

  • 生物制剂初治患者平均随访时长3.6±2.4年,共发生9988次治疗中断。
  • Kaplan-Meier生存分析显示第1年持续性61.9%、第3年33.3%、第5年22.6%。
  • 乌司奴单抗持续性高于其他生物制剂,但鉴于生物制剂给药方式差异,此发现需谨慎解读。
  • 约85%停用首个生物制剂的患者在次年重新接受某种系统治疗,其中85%为生物制剂。

局限性

  • 乌司奴单抗持续性高于其他生物制剂的发现需谨慎解读,因生物制剂给药方式存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term clinical effectiveness of biologics in psoriasis is needed. OBJECTIVES: We aimed to assess the long-term persistence of biologics used to treat psoriasis in a real-life setting. METHODS: All adults with psoriasis having been registered in the French National Health Insurance database (SNIIRAM) between 2008 and 2016 were eligible for inclusion. Psoriasis was defined as the fulfilment of at least two prescriptions for topical formulations of a vitamin D derivative within a 2-year period. The study population comprised biologic-naïve patients, i.e. those with a first prescription of etanercept, infliximab, adalimumab or ustekinumab. Persistence of treatment with a biologic was defined as the time interval between initiation and discontinuation. RESULTS: In this nationwide population-based cohort, 16 545 out of 874 549 patients with psoriasis were biologic-naïve (mean age 48·6 years; males 57·3%, mean follow-up 3·6 years). The mean ± SD length of follow-up for biologic-naïve patients was 3·6 ± 2·4 years. There were 9988 treatment discontinuations. Kaplan-Meier survival analyses revealed a persistence rate of 61·9% for the first, 33·3% for the third and 22·6% for the fifth year. Ustekinumab had a higher persistence rate than the other biologics. This finding should be interpreted with caution, in view of differences in administration between the biologics. About 85% of patients, having discontinued their first biologic, resumed systemic treatment of some type in the following year (biologics in 85% of cases). CONCLUSIONS: Our data suggest that biologics are less effective than physicians have been led to believe in a real-life, nonselected population. Further, long-term disease control requires several courses of different biologics.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Sbidian E, Mezzarobba M, Weill A, et al. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM). Br J Dermatol. 2018. PMID: 29791721. doi:10.1111/bjd.16809

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。